Related Experiment Video

Updated: Oct 2, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.2K

Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia

Ioannis Parthymos1, Michael S Kostapanos2, George Liamis1

  • 1Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece.

Journal of Cardiovascular Development and Disease
|February 24, 2022
PubMed

Insights

New therapies are emerging to manage severe hypertriglyceridemia when existing treatments fail. This review covers novel agents like apolipoprotein C-III inhibitors and FGF21 analogues for better cardiovascular risk reduction.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Hypertriglyceridemia is a significant risk factor for cardiovascular disease and acute pancreatitis.
  • Current treatments like fibrates and omega-3 fatty acids are often insufficient for very high triglyceride levels and residual cardiovascular risk in mixed dyslipidemia.

Purpose of the Study:

  • To review the latest and experimental therapies for managing hypertriglyceridemia.
  • To discuss ongoing clinical trials for novel triglyceride-lowering agents.

Main Methods:

  • Literature review of current and emerging treatments for hypertriglyceridemia.
  • Focus on novel therapeutic classes currently in early clinical development.

Main Results:

  • Several novel agents are in development, including apolipoprotein C-III inhibitors, advanced omega-3 fatty acids, and fibroblast growth factor 21 (FGF21) analogues.
  • These experimental therapies aim to address the unmet need in patients with severe hypertriglyceridemia and mixed dyslipidemia.

Conclusions:

  • Novel therapeutic strategies targeting apolipoprotein C-III and FGF21 show promise for managing hypertriglyceridemia.
  • These emerging treatments may offer improved outcomes for patients with high cardiovascular risk due to dyslipidemia.
Keywords:
apolipoprotein C-IIIfibroblast growth 21 factorlipoprotein lipasetriglyceridesvolanesorsenω-3 fatty acids

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
929
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
315
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
267
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
271
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236